Shire PLC (ADR)  

(Public, NASDAQ:SHPG)   Watch this stock  
Find more results for NASDAQ:SHPGY
-0.76 (-0.36%)
Real-time:   2:41PM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 208.31 - 212.00
52 week 196.01 - 270.63
Open 211.32
Vol / Avg. 548,687.00/1.00M
Mkt cap 41.94B
P/E 13.57
Div/yield 0.13/0.33
EPS 15.45
Shares 600.50M
Beta 0.88
Inst. own 8%
Feb 15, 2016
Full Year 2015 Shire PLC Earnings Release (Estimated) Add to calendar
Dec 3, 2015
Shire PLC at Deutsche Bank dbAccess Pharmaceutical Corporate Day Add to calendar
Dec 1, 2015
Shire PLC at Piper Jaffray Healthcare Conference - 8:30AM EST - Add to calendar
Nov 18, 2015
Shire PLC at Jefferies Global Healthcare Conference
Nov 2, 2015
Shire PLC at �EBD BIO Europe- Fall
Oct 23, 2015
Q3 2015 Shire PLC Earnings Call
Oct 23, 2015
Q3 2015 Shire PLC Earnings Release
Sep 30, 2015
Shire PLC at Leerink Partners Rare Disease Roundtable
Sep 17, 2015
Shire PLC at Morgan Stanley Healthcare Conference
Sep 17, 2015
Shire PLC at Bank of America Merrill Lynch Global Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin 28.87% 54.47%
Operating margin 27.54% 28.20%
EBITD margin - 43.82%
Return on average assets 11.11% 29.88%
Return on average equity 20.50% 46.80%
Employees 5,016 -
CDP Score - 91 B


5 Riverwalk Citywest Business Campus, Dublin 24
+353-1-4297700 (Phone)
+353-1-4297701 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Shire plc is a biopharmaceutical company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other specialty conditions. The Company commercializes its products in the areas of Neuroscience, Gastrointestinal (GI), Rare Diseases and Other therapeutic areas. The Company’s products include VYVANSE/VENVANSE/ELVANSE/TYVENSE/ELVANSE VUXEN/ADUVANZ (lisdexamfetamine dimesylate), ADDERALL XR (mixed salts of a single-entity amphetamine), INTUNIV (extended release guanfacine), EQUASYM (methylphenidate hydrochloride) modified release (XL), BUCCOLAM, LIALDA (mesalamine)/ MEZAVANT(mesalazine), PENTASA (mesalamine), RESOLOR (prucalopride), REPLAGAL (agalsidase alfa), VPRIV (velaglucerase alfa), FIRAZYR (icatibant), CINRYZE C1 esterase inhibitor (human), FOSRENOL (lanthanum carbonate), XAGRID/ AGRYLIN (anagrelide hydrochloride) and PLENADREN (modified release hydrocortisone).

Officers and directors

Flemming Ornskov M.D. Chief Executive Officer, Executive Director
Age: 57
Bio & Compensation  - Reuters
Jeffrey Poulton Chief Financial Officer, Director
Age: 47
Bio & Compensation  - Reuters
Ginger Gregory Chief Human Resource Officer
Bio & Compensation  - Reuters
Mark J. Enyedy Interim General Counsel, Head of Corporate Development
Age: 51
Bio & Compensation  - Reuters
Phil J. Vickers Head of Research and Development
Age: 55
Bio & Compensation  - Reuters
Susan Saltzbart Kilsby Non-Executive Chairman of the Board
Age: 56
Bio & Compensation  - Reuters
David J. Kappler Senior Independent Non-Executive Deputy Chairman of the Board
Age: 68
Bio & Compensation  - Reuters
Olivier Bohuon Non-Executive Director
Age: 56
Bio & Compensation  - Reuters
Sara Mathew Non-Executive Director
Age: 60
Bio & Compensation  - Reuters
Dominic Blakemore Non-Executive Independent Director
Age: 45
Bio & Compensation  - Reuters